Dare Bioscience DARE 深 沪
等待开盘 09-09 09:30:00 美东时间
2.13
-0.020
-0.93%
华盛通- 最 高2.16
- 今 开2.16
- 成交量 14.48万股
- 最 低 2.05
- 昨 收 2.15
- 总市值 2871.13万
- 52周最高 9.19
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 1.83
- 委 比 -47.88%
- 总股本 1347.95万
- 历史最高 76.44
- 量 比 1.02
- 振 幅 5.12%
- 历史最低 1.83
- 每 手 1
- 风险率 0.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Daré, AMD, Twilio, UiPath, Luckin: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($DARE) ), ( ($AMD) ), ( ($TWLO) ),...
09-06 17:01
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-04 22:05
Maxim Group Upgrades Dare Bioscience to Buy, Announces $8 Price Target
Maxim Group analyst Caroline Palomeque upgrades Dare Bioscience (NASDAQ:DARE) from Hold to Buy and announces $8 price target.
09-04 20:12
Dare Bioscience Q2 EPS $(0.45) Beats $(0.61) Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.61) by 26.83 percent. This is a 129.61 percent decrease over earnings of $1.52 per share from
08-15 04:03
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
A Preview Of Dare Bioscience's Earnings
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings repo...
08-14 00:02
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
Daré Bioscience will host a conference call on August 14, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide an update. The call can be accessed via phone (646-307-1963 or 800-715-9871) with conference ID 2684883, or via live webcast at ir.darebioscience.com. The company, focused on women’s health, has several innovative products in development, including XACIATO for bacterial vaginosis, Ovaprene for contraception, Sildena...
08-07 12:00
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
Daré Bioscience and Rosy Wellness announce the launch of DARE to PLAY Sildenafil Cream, a topical formulation for women’s arousal, set to be available by prescription in Q4 2025. The campaign includes educational content, short video series, and expert-led modules to raise awareness and support women with arousal concerns. The collaboration aims to bridge gaps in women’s sexual health information and access.
07-29 12:00
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Daré Bioscience introduces DARE to PLAY™, the first sildenafil cream for women, to address sexual arousal issues. Formulated to improve blood flow and response, it’s set for prescription availability in Q4 2025.
07-21 12:00
3 Penny Stocks to Watch Now, 7/15/25
Dare Bioscience, LQR House, and Canaan Inc. are the 3Penny Stocksto...
07-15 19:04
